Century Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC), an emerging growth company incorporated in Delaware. The report covers events occurring on June 15, 2026, and was signed on June 16, 2026, by Brent Pfeiffenberger, President, CEO, and Chairman.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in executive compensation arrangements.
Material Changes
On June 15, 2026, the Company entered into an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., its Chief Scientific Officer. Key changes include:
- Role Adjustment: Dr. Cowan will continue as Chief Scientific Officer on a part-time basis.
- Compensation Reduction: His annual salary is reduced to $296,150.
- Bonus Structure: He remains eligible for an annual performance-based target bonus on a pro-rated basis.
- Termination Terms: Upon termination or resignation, Dr. Cowan is entitled to all accrued and unpaid base salary through the cessation date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The full text of the Amended and Restated Agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
Investor Verification Checklist
- Verify the impact of the Chief Scientific Officer's transition to part-time status on ongoing research and development timelines.
- Review the full Amended and Restated Employment Agreement in the upcoming Form 10-Q for detailed bonus metrics and termination clauses.
- Confirm if this compensation adjustment is part of a broader cost-reduction strategy or isolated to this executive role.